DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.

Yu Jian Shao Yonglu Chen Mingyue ZhuYuanyuan LiuChen FangMinjun WangPeng SunWeiling FuJing HuangShimei ShengYanshan Huang

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2024)

mice, and substantial body weight reduction and metabolism improvement in DIO mice. DR10627 is a promising agent deserving further investigation for the treatment of type 2 diabetes and obesity.

Keyphrases

high fat diet induced
body weight
insulin resistance
metabolic syndrome
type diabetes
weight loss
cardiovascular disease
physical activity
editorial comment
body mass index
skeletal muscle
replacement therapy
combination therapy
glycemic control
cardiovascular risk factors
smoking cessation